To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been investigated but with few reported comparisons. We compared an intensified regimen of etoposide (60 mg/kg), busulphan (14 mg/kg), and cyclophosphamide (120 mg/kg) (BuCyVP) with BuCy2 in 237 AML patients. No significant difference in overall outcome was observed following BuCyVP (n ¼ 127) or BuCy2 (n ¼ 110). The 5-year survival was 27.3 and 30.1% following BuCyVP and BuCy2, respectively (P ¼ 0.48). Similarly, the 5-year cumulative incidence of relapse (CIR) was 28.3 and 34.8% with BuCyVP and BuCy2 (P ¼ 0.45), respectively. On multivariable analysis, patients transplanted in CR1 (P ¼ 0.002) and from related donors (P ¼ 0.013) had longer survival, while disease status at transplant was the only factor predicting CIR (P ¼ 0.002). In a separate analysis of CR1 patients (n ¼ 56), there was no significant difference in survival (P ¼ 0.37) or CIR (P ¼ 0.87) between the two regimens. However, for more advanced disease, there was a trend towards less relapse with BuCyVP (P ¼ 0.08), which was balanced by a higher cumulative incidence of transplant-related deaths (P ¼ 0.03) compared to BuCy2, resulting in similar survival. Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients. etoposide High-dose chemotherapy followed by allogeneic transplantation of hematopoietic stem cells is an important curative modality for many patients with acute myeloid leukemia (AML). The optimum intensity of the preparative regimen in this setting, however, remains uncertain. Almost two decades ago, the combination of high-dose busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) without total body irradiation (TBI) was shown to permit successful hematopoietic engraftment and control of disease in many patients with leukemia.
etoposide High-dose chemotherapy followed by allogeneic transplantation of hematopoietic stem cells is an important curative modality for many patients with acute myeloid leukemia (AML). The optimum intensity of the preparative regimen in this setting, however, remains uncertain. Almost two decades ago, the combination of high-dose busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) without total body irradiation (TBI) was shown to permit successful hematopoietic engraftment and control of disease in many patients with leukemia. 1, 2 Subsequently, modification of the regimen by lowering the dose of cyclophosphamide to 120 mg/kg (BuCy2) appeared to be less toxic without loss of efficacy. 3, 4 In three of five randomized trials comparing BuCy2 with TBI-based regimens in patients with chronic phase chronic myeloid leukemia (CML) and advanced acute leukemia, the BuCy2 regimen was associated with equivalent survival. [5] [6] [7] In spite of the potential for a graftversus-tumor effect, however, disease recurrence remains a significant cause of treatment failure following high-dose busulfan/cyclophosphamide and allogeneic stem cell transplantation, particularly in more advanced or refractory AML where over half of the patients relapse. 3, 8 In an attempt to reduce relapse and improve overall outcome, several groups have intensified the busulfan/cyclophosphamide regimen by combining it with either TBI [9] [10] [11] or other chemotherapy agents, including high-dose thiotepa, 12, 13 cytarabine, 14, 15 melphalan, 16 or etoposide. [17] [18] [19] [20] The relative efficacy of these intensified regimens compared to busulfan/cyclophosphamide has been difficult to determine as many studies have been small and few comparisons between have been performed. Of chemotherapy agents, high-dose etoposide, in a variety of doses and schedules, has been the most commonly investigated drug in combination with busulfan and cyclophosphamide. [18] [19] [20] [21] Etoposide has excellent antineoplastic activity against a variety of myeloid and lymphoid malignancies and shows a steep dose response with minimal extramedullary toxicity in standard doses. 22 As a topoisomerase II inhibitor, it displays synergistic activity with alkylating agents, and is therefore suited to combination with busulfan and cyclophosphamide. We investigated the efficacy of combining etoposide 60 mg/kg with a modification of the BuCy2 regimen using a lower busulfan dose of 14 mg/kg based on dose escalation studies suggesting less hepatorenal toxicity at this dose. 23, 24 The regimen was well tolerated in lymphoma patients undergoing autologous blood stem cell transplantation, 25 although direct comparisons with other regimens was not performed. In this study, we compare the intensified regimen of high-dose busulfan (14 mg/kg), etoposide, and cyclophosphamide (BuCyVP) with standard BuCy2 in AML patients undergoing allogeneic hematopoietic progenitor cell transplantation.
Patients and methods

Patients
This study includes 237 adult AML patients who received a first allogeneic hematopoietic progenitor cell transplant following busulfan and cyclophosphamide with or without etoposide at the Ohio State University and the Cleveland Clinic Foundation. The results of 110 patients who received BuCy2 and 127 patients treated with BuCyVP on prospective protocols were analyzed. In both institutions, BuCy2 was used on a prospective protocol between January 1984 and March 1994 for consecutive AML patients, eligible for related or unrelated allogeneic transplantation, regardless of remission status at the time of transplant, while BuCyVP was similarly used between April 1994 and December 2001. Both protocols were approved by the institutional review boards at both institutions and patients gave written informed consent. The primary objective was to compare the overall survival (OS), cumulative incidence of relapse (CIR), and toxicity with BuCyVP and BuCy2. Patients received unmanipulated bone marrow or peripheral blood stem cells from HLAmatched related or unrelated donors. All patients had AML as defined by the French-American-British (FAB) criteria. 26 Patients with myelodysplastic disorders were excluded from analysis, except for patients with refractory anemia with excess blasts in transformation who are now classified as AML under the recent WHO classification. 27 Patients were considered to have low-risk disease for relapse if they had AML first complete remission, while patients beyond first remission were considered as highrisk. All patients were required to have a Karnofsky performance status X60%, FEV1 and FVC X60% of predicted values, cardiac ejection fraction X40%, and serum creatinine p2 mg/dl at the time of transplant.
Preparative regimens
Patients treated with BuCy2 received busulfan 1 mg/kg orally every 6 h for 16 doses, followed by cyclophosphamide 60 mg/kg intravenously on each of the next 2 days, as previously described.
3.
The BuCyVP regimen administered busulfan at a dose of 1 mg/kg orally every 6 h for 14 doses beginning 8 days prior to progenitor cell infusion. Etoposide 60 mg/kg was initiated 2 h after the last dose of busulfan as a 36 h continuous intravenous infusion. Cyclophosphamide 60 mg/kg was then administered intravenously on each of the next 2 successive days. 25 Following each regimen, progenitor cells were infused approximately 48 h after the second dose of cyclophosphamide. Prophylactic phenytoin was administered prior to and during busulfan administration. According to protocol, the doses of busulfan and cyclophosphamide were based on the lower of ideal body weight (IBW) or real body weight (RBW) unless the RBW exceeded IBW by 20%. In that case, an adjusted ideal body weight (AIBW), the IBW plus 25% of the difference between IBW and RBW, was used.
Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine or tacrolimus with methotrexate. Patients developing grades II-IV acute GvHD were uniformly treated with corticosteroids. All patients received prophylactic antibacterial antibiotics and antifungal agents with either low-dose amphotericin-B or fluconazole. As ganciclovir became commercially available, it was routinely used for cytomegalovirus prophylaxis or initiated preemptively when viral reactivation was detected on weekly surveillance viral blood cultures.
Statistical analysis
Baseline clinical characteristics were compared for patients who received BuCy2 and BuCyVP using the w 2 or Fisher's exact tests for categorical variables and the Mann-Whitney test for continuous variables. Overall survival was measured from the time of transplant until death regardless of cause, censoring for patients alive. The cumulative incidence of relapse or progression was calculated from the time of transplant until relapse or death, except that death in remission was regarded as a competing risk. Estimates of OS were calculated using the Kaplan-Meier method, 28 and differences in survival were compared using the log-rank test. Estimates of CIR, accounting for deaths as a competing risk, were calculated and the difference among treatment groups was determined by Gray's k-sample test. 29 The incidence of acute and chronic GvHD, venoocclusive disease (VOD), and transplant mortality rates for patients receiving BuCyVP and BuCy2 were determined by using the w 2 or Fisher's exact tests as appropriate. To study the independent effect of the preparative regimen, controlling for other baseline clinical factors, including age, gender, remission status at transplant, donor type, and stem cell source, a Cox proportional hazards model was constructed for OS, and a multivariable model using Gray's competing risk regression method was constructed for CIR, 30 using a backward selection strategy. For all analyses, a two-sided a-value of 0.05 was considered significant.
Results
Patients characteristics
The baseline clinical characteristics of all patients included in this study are shown in Table 1 . As a group, patients who received BuCyVP were significantly older compared to patients treated with BuCy2. The median age of patients treated with BuCy2 was 35 (range 18-61) years compared to a median age of 40 (range 17-62) years for patients who received BuCyVP, with six (5.5%) and 23 (18%) of patients in each group, respectively, older than 50 years. There were additional significant imbalances in the distribution of baseline characteristics between the two groups. In total, 66% of patients in the BuCy2 group had high-risk disease compared to 86% of patients in the BuCyVP group (Po0.001). The majority of patients received stem cells from HLA-matched related donors, although a significantly higher proportion of patients in the BuCyVP group received matched unrelated donor transplants (11 vs 34%, Po0.001). As patients treated with BuCyVP were more recently transplanted, the median follow-up for surviving patients in this group was 4.3 (range, 0.8-9.4) years, significantly shorter than the median follow-up of 10.9 (range, 1.2-19.6) years for BuCy2-treated patients (Po0.001).
OS
There was no significant difference in OS of patients receiving BuCyVP and BuCy2. The median OS of patients treated with BuCyVP was 0.7 year compared to 1 year for patients treated with BuCy2 (P ¼ 0.48). At 5 years, the estimated OS of patients treated with BuCyVP is 27.3% (95% confidence interval (CI), 18.9-35.6%) compared to 30.1% (95% CI, 20.2-39.1%) for the BuCy2 treated patients ( Figure 1a ). As the similar outcome for the two regimens may be confounded by significant imbalances in important baseline clinical variables between the two groups (Table 1) , we performed a Cox regression analysis to identify independent factors affecting survival and relapse in the entire study population. The results of univariate and multivariable analyses, including the variables age, gender, period of transplant, donor type (matched sibling vs unrelated donor), disease risk (CR1 vs beyond CR1) at time of transplant, and preparative regimen, are shown in Table 2 . In the multivariable analysis, preparative regimen was forced into the final model. Disease risk and donor type were the only significant predictive factors for OS on both univariate and multivariable analysis. Controlling for the other factors, AML patients in CR1 had almost one half the chance of dying compared to patients transplanted beyond first CR (hazard ratio of death (HR) 0.55, 95% CI: 0.37-0.80; P ¼ 0.004). Similarly, transplantation from matched sibling donors was associated with an improved OS compared to that from unrelated donors (HR 0.64, 95% CI: 0.45-0.91; P ¼ 0.012). Importantly, the preparative regimen was not significantly predictive of OS on multivariable analysis (P ¼ 0.54). A similar analysis restricted only to patients who received transplants from matched sibling donors revealed a similar result, with only high-risk disease predicting shorter OS (P ¼ 0.007), while no significant effect of the type of preparative regimens was observed (P ¼ 0.94), on multivariable analysis. Similarly, for matched unrelated donor transplants only, a significant effect of the type of preparative regimen on OS was not observed (P ¼ 0.40), although the analysis is limited by the relatively small number of such transplants performed. Figure 2a and b show the OS of patients with low-and high-risk disease, respectively, comparing the BuCyVP and BuCy2 regimens. Although the median OS of AML patients in CR1 treated with BuCyVP was not reached compared to 1.8 years for patients treated with BuCy2, the difference was not statistically significant (P ¼ 0.37). At 5 years, the estimated OS of patients transplanted in first remission using BuCyVP was 55.6% (95% CI, 32.1-78.9%) compared to 41.2% (95% CI, 24.9-57.4%) for those treated with BuCy2. Among patients with high-risk disease, the median OS of patients treated with BuCyVP was 0.6 years compared to 0.7 years for those treated with BuCy2 (P ¼ 0.71). The 5-year OS of high-risk patients treated with BuCyVP was 21.9% (95% CI, 13.1-30.6%) compared to 24.2% (95% CI, 13.9-34.5%) for those treated with BuCy2.
CIR
Overall, no significant difference in the CIR was observed between the two regimens (Figure 1b) . The 5-year CIR was 28.3% (95% CI, 20.2-36.3%) for patients treated with BuCyVP, compared to 34.8% (95% CI, 25.7-43.8%) for patients treated with BuCy2 (P ¼ 0.45). Table 3 shows the results of univariable and multivariable analyses examining the relationship between age, gender, period of transplant, donor type, disease risk, and preparative regimen. Disease status at transplant emerged as the only significant variable predictive of relapse on univariate (P ¼ 0.004) and multivariable analysis (P ¼ 0.002), with patients beyond first CR at the time of transplantation having three to four times the risk of relapse compared to patients transplanted in CR1. Use of either preparative regimen was not associated with relapse, even after controlling for other variables (P ¼ 0.21).
The CIR for low-and high-risk patients, comparing BuCyVP and BuCy2, is shown in Figure 3a and b, respectively. For patients transplanted in CR1, the 5-year CIR was similar in patients treated with BuCyVP (11.1%, 95% CI: 0-26.1%) compared to patients treated with BuCy2 (13.3%, 95% CI: 2.13-24.5%) (P ¼ 0.87). On the other hand, for high-risk patients, there was a trend towards a lower 5-year risk of relapse in patients treated 
Treatment-related complications
No significant differences were observed in treatmentrelated complications with BuCyVP and BuCy2 (Table 4) . Grades II-IV acute GvHD occurred in 42.5% of patients treated with BuCyVP compared to 39.1% of those who received BuCy2 (P ¼ 0.59). Similarly, there was no difference in the incidence of limited (17.3 vs 16.5%, P ¼ 0.91) and extensive (34.6 vs 43.0%, P ¼ 0.15) chronic GvHD in patients treated with BuCyVP and BuCy2, respectively. VOD of the liver occurred in 28% of patients who received BuCyVP compared to 27% of those treated with BuCy2 (P ¼ 0.89).
Treatment-related mortality
As shown in Table 4 , treatment-related mortality at days 30 and 100 after transplantation was also similar in patients treated with either regimen (P ¼ 0.26 and P ¼ 0.29, respectively). Table 5 lists the causes of death at 100 days post transplant with the two regimens. The commonest causes of death were acute GvHD and multiorgan failure syndrome, which occurred with similar frequency with both regimens. There was a trend for more infection deaths with the BuCyVP regimen, where infections were due to CMV (n ¼ 3), invasive fungal infection (n ¼ 2), and bacteria (n ¼ 2), compared to only one infection death with BuCy2 (P ¼ 0.05). No fatal cases of interstitial pneumonitis were observed in either group. To better investigate the relative effect of the regimens on treatment-related deaths beyond 100 days, we analyzed the cumulative incidence of death from treatment taking account of relapse as a competing risk. Deaths beyond 100 days after transplant were considered treatment-related if they were due to complications of acute or chronic GvHD, infections, or late secondary malignancies. Patients dying of unrelated causes were censored. The univariable comparison of the cumulative incidence of treatmentrelated death for the two regimens is shown in Figure 4a , and separately for low-risk and high-risk patients in Figure  4b and c, respectively. A significantly higher cumulative incidence of treatment-related deaths was associated with the BuCyVP regimen in high-risk patients (P ¼ 0.03), which was not observed in low-risk patients (P ¼ 0.50). At 5 years, the risk of treatment-related death with BuCyVP in patients transplanted beyond CR1 was 47.3% (95% CI, 37.4-57.3) compared to 29.2% (95% CI, 18.6-39.8%) with BuCy2. For all patients, multivariable analysis including age, gender, period of transplant, donor type, risk status at the time of transplant, and preparative regimen as covariates, BuCyVP remained an independent adverse risk factor with a HR of treatment-related death of 1.92 (95% CI, 1.01-3.66; P ¼ 0.046), together with transplantation from a matched unrelated donor (HR 2.17, 95% CI: 1.34-3.56; P ¼ 0.002).
Discussion
High-dose busulfan and cyclophosphamide is one of the most commonly used standard myeloablative regimens for allogeneic hematopoietic stem cell transplantation of AML, with similar efficacy to TBI-based regimens. 31 While intensifying the preparative regimen by the addition of a variety of chemotherapeutic agents to high-dose busulfan and cyclophosphamide have been reported to be well tolerated, few disease-specific comparative studies have been reported. In this large study with a median follow-up of over 5 years, we demonstrated that intensification of high-dose busulfan and cyclophosphamide by the addition of etoposide does not improve outcome of AML patients undergoing allogeneic hematopoietic progenitor cell transplantation.
Our study is consistent with previous reports indicating that the addition of etoposide to busulfan and cyclophosphamide is well tolerated. 19, 21 Specifically, the BuCyVP regimen was not associated with increased early fatal toxicity as assessed by TRM at days 30 and 100 post transplantation when all patients were analyzed, and also when TRM was assessed separately in low-and high-risk patients (results not shown). Similarly, the incidence of Table 5 Cause of death at 100 days after transplantation
Acute GvHD  12  11  Alveolar hemorrhage  1  2  VOD  1  2  Multiorgan failure syndrome  7  7  Infection  1  7  Graft failure  0  1  CNS hemorrhage  0  1  Other  1  3 VOD was almost identical to that of patients treated with BuCy2, although it should be noted that the busulfan dose was lower (14 mg/kg) in patients receiving BuCyVP, which may have influenced the result. 32, 33 It remains unknown if a higher incidence of VOD would have resulted if 16 mg/kg of busulfan was also used in the BuCyVP regimen. No fatal cases of interstitial pneumonitis were observed with the BuCyVP or BuCy2 regimens. Although a similar regimen of etoposide, busulfan, and cyclophosphamide was reported to be associated with severe pulmonary toxicity, this was largely confined to patients who had previously received mediastinal irradiation; 34 none of our patients had received prior radiation therapy.
It is important to note that the comparable tolerability of our BuCyVP regimen was achieved in spite of a higher dose of etoposide (60 mg/kg). Spitzer et al 35 determined a maximum tolerated dose of etoposide of 30 mg/kg when combined with busulfan-containing regimens. In combination with busulfan (16 mg/kg) and cyclophosphamide (150 mg/kg), Jones et al 36 observed that hepatic toxicity and mucositis were dose limiting at 50 mg/kg of etoposide. In a later study, etoposide at a dose of 60-65 mg/kg in combination with busulfan (or TBI) and cyclophosphamide was associated with a significantly increased incidence of life-threatening or fatal toxicities compared with a combination using a dose of 25-50 mg/kg. 37 More recently, an etoposide dose of 30 mg/kg was found to be associated with less toxicity and better OS due to lower TRM compared to a dose of 45 mg/kg, when the drug was combined with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). 19 Although we used a lower dose of busulfan (14 mg/kg), the administration of etoposide as a prolonged continuous infusion over 36 h, known to alter the cytotoxicity of the drug, 38 may have contributed to the tolerability of this dose in our study. In spite of the higher dose, however, the 100-day mortality was not higher than that previously reported when lower doses of etoposide were combined with busulfan and cyclophosphamide. 19 Excellent results have been reported when etoposide was combined with busulfan and cyclophosphamide in AML patients in first remission who received allogeneic stem cell transplants, although comparison with standard BuCy2 was not performed. In a series of 31 patients aged 4-51 years with AML in CR1 treated with 16 mg/kg busulfan, 30-60 mg/kg etoposide and 120 mg/kg cyclophosphamide, no relapses were reported with 25 patients remaining alive in continuous CR after a median follow-up of 30.5 months. 21 Similar results were observed in another study comparing 30 and 45 mg/kg of etoposide in combination with BuCy2, where no relapses were observed in 28 patients. 19 Our results in low-risk patients are consistent with the latter report, with only two of 17 patients transplanted in CR1 following BuCyVP in our study relapsing. However, this was not significantly different to the result observed with BuCy2 where six of the 32 patients relapsed, where follow-up was significantly longer. Indeed, there was no difference in the CIR between the two regimens for low-risk patients (P ¼ 0.87). Importantly, while the OS of patients treated with BuCyVP was excellent, it was not significantly different to that of patients treated with BuCy2, indicating no significant advantage to the addition of etoposide to high-dose busulfan and cyclophosphamide in low-risk patients.
A rationale for the development of more intensive preparative regimens is to reduce the risk of relapse in patients with more advanced disease. In a study of 24 patients with advanced hematological malignancies, including 10 AML patients, the regimen of etoposide (60 mg/ kg), busulfan (16 mg/kg), and cyclophosphamide was associated with superior outcome compared to patients undergoing allogeneic transplants following conditioning with a variety of TBI-based regimens due, at least in part, to a reduction in relapse. 18 In addition, although the combination of etoposide with BuCy2 was considered to have acceptable TRM in this population (38% at 100 days post transplant), with promising potential for reducing relapse and therefore improving survival, comparison with BuCy2 was not performed. Other series have also reported the use of etoposide with busulfan and cyclophosphamide in allogeneic transplantation, although conclusions regarding the relative efficacy of the preparative regimen are not possible. 12, 20, 39, 40 In our study, a trend towards a reduction in the CIR with the more intensive regimen, BuCyVP, was observed, although this likely did not reach statistical significance because of our small sample size. However, any potential advantage of BuCyVP in reducing the risk of relapse was balanced by increased incidence of treatmentrelated deaths, relative to BuCy2 (P ¼ 0.03), particularly beyond 100 days after transplant. This was mostly related to fatal chronic GvHD and its associated complications, including opportunistic infections (data not shown). Therefore, the survival of high-risk patients was almost identical with the two preparative regimens.
A limitation of our study is that the comparison of the two regimens was not performed in a randomized manner. In addition, as our analysis combined data from parallel protocols in two institutions, the potential for center bias was possible. However, as each institution used a given regimens for consecutive AML patients undergoing myeloablative allogeneic transplants during defined time periods, regardless of patients risk or donor type, the potential for selection bias is minimized. Furthermore, for each of the BuCy2 and BuCyVP regimens, respectively, there was no significant difference in OS, CIR, or 30-day and 100-day treatment-related mortality between the two institutions (P40.38 for all outcomes; data not shown), suggesting the absence of significant center bias. Nonetheless, while it is possible that inadvertent assignment bias against BuCyVP may have been present, particularly as patients treated with BuCyVP were transplanted more recently where there may have been a greater willingness to take higher risk and older patients to allogeneic transplantation, we believe that it is unlikely that the results would be different if a randomized study is performed. In the absence of randomized trials, our study is the largest published comparison of the outcome of an intensified regimen with standard BuCy2. However, it is important to note that as the dose of busulfan in BuCyVP was 13% lower than that in BuCy2, our analysis did not simply investigate the effect of adding etoposide to BuCy2, as previously tested. 12, 18, 20, 39, 40 Nonetheless, in spite of the reduced dose of busulfan, we believe that BuCyVP is a more intensive regimen than BuCy2. While our results do not exclude the possibility that other intensive regimens that include other additional cytotoxic agents or TBI may improve outcome, our results suggest that beyond a certain level of doseintensity a plateau in leukemic cell killing is reached and that more cures are likely to result from the immunological effects of allogeneic transplantation. This is consistent with the encouraging results observed with nonmyeloablative regimens, which rely more heavily on the graft-versusleukemia effect. We conclude, therefore, that the addition of etoposide (and potentially other chemotherapy drugs or TBI) to high-dose busulfan and cyclophosphamide regimens is unlikely to improve the outcome in AML patients with either early or more advanced disease. Improvement in outcome is likely to result from better harnessing the graftversus-leukemia effect while preventing GvHD.
